In 2010, the Bill & Melinda Gates Foundation launched an initiative to eradicate preventable diseases through the discovery, development, and delivery of vaccines worldwide. This leadership prepared the Foundation to respond boldly and immediately to the COVID-19 pandemic. To date, the Foundation has committed $250 million to accelerate the development of COVID-19 diagnostics, therapeutics, and vaccines and to make them available throughout the world. Its investments include $75 million to create the COVID-19 Therapeutics Accelerator (which which was founded with another $75M from Wellcome Trust and Mastercard, and which is now bundling investments from additional philanthropists. The Gates Foundation also rapidly established the Combating COVID-19 Fund within the foundation’s public charity, Gates Philanthropy Partners, which pools donations from other funders to fast track R&D for diagnostics and vaccines. Join us to hear about the Gates Foundation’s COVID-19 strategy and what it is learning.
On Thursday, May 28 at 4 p.m. ET, we'll be joined by Jennifer Alcorn, Deputy Director of Philanthropic Partnerships leading the Private Donor Engagement portfolio at the Bill & Melinda Gates Foundation.